SC 13G/A: MoonLake Immunotherapeutics

AI Summary

SC 13G/A filing by MoonLake Immunotherapeutics.

Risk Assessment

Risk Level: low

FAQ

Key Financial Figures

• $0.0001 — er) Class A ordinary share, par value $0.0001 per share (Title of Class of Securiti

Filing Documents

• tm246392d1_sc13ga.htm (SC 13G/A) — 83KB
• tm246392d1_ex99-1.htm (EX-99.1) — 9KB
• tm246392d1_ex99-2.htm (EX-99.2) — 12KB
• 0001104659-24-024363.txt ( ) — 106KB

(a)

Item 1(a). Name of Issuer: MoonLake Immunotherapeutics

(b)

Item 1(b). Address of Issuer’s Principal Executive Offices: Dorfstrasse 29 Zug, Switzerland 6300

(a)

Item 2(a). Name of Person Filing: This Schedule 13G is being filed by each of the following persons (each, a “Reporting Person” and together, the “Reporting Persons”): Merck Healthcare KGaA, Darmstadt, Germany an affiliate of Merck KGaA Darmstadt Germany Merck KGaA, Darmstadt, Germany E.Merck KG, Darmstadt, Germany The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which the Reporting Persons have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k)(l) of the Securities Exchange Act of 1934, as amended.

(b)

Item 2(b). Address of Principal Business Office or, if none, Residence: Merck Healthcare KGaA, Darmstadt, Germany an affiliate of Merck KGaA Darmstadt, Germany, and Merck KGaA: Frankfurter Strasse 250, 64293 Darmstadt, Germany E.Merck KG: Emanuel-Merck-Platz 1, 64293 Darmstadt, Germany

(c)

Item 2(c). Citizenship: The Reporting Persons Merck Healthcare KGaA an affiliate of Merck KGaA Darmstadt Germany, Merck KGaA and E.Merck KG are organized in Germany.

(d)

Item 2(d). Title of Class of Securities: Class A ordinary shares, par value $ 0.0001 per share

(e)

Item 2(e). CUSIP Number: G4444C102 Item 3. If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a: Not applicable (a) o Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o); (b) o Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c); (c) o Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c); (d) o Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); (e) o An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E); (f) o An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F); (g) o A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); (h) o A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) o A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3); (j) o A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J); (k) o Group, in accordance with § 240.13d-1(b)(1)(ii)(K). Cusip No. G4444C102 13G Page 6 of 7 Pages Item 4. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: Each of the Reporting Persons may be deemed to beneficially own 2,787,509 Class A ordinary shares. See notes 1, 3 and 5 on the Cover Pages, which are incorporated herein. (b) Percent of class: 4.7%; see notes 2, 4 and 6 on the Cover Pages, which are incorporated herein. (c) Number of shares as to which the Reporting Persons have: (i) Sole power to vote or to direct the vote: 2,787,509 (ii) Shared power to vote or to direct the vote: 0 (iii) Sole power to dispose or to direct

View Full Filing

View this SC 13G/A filing on SEC EDGAR